1275 Carriage of Pnpla3 I148m Is Associated With an Increased Risk of Non-Alcoholic Fatty Liver Diesease Associated Hepatocellular Carcinoma

Liu, Y.-L.; Patman, Gillian; Leathart, Julian; Burt, Austin; Day, Chris; Daly, Ann K.; Reeves, H.L.; Anstee, Quentin M.

doi:10.1016/s0168-8278(13)61276-3

Cited by 7 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The association between the I148M variant and fibrosis is also evident in chronic viral hepatitis and genetic diseases, such as hereditary haemochromatosis [69][70][71]. In addition, the I148M variant predisposes to hepatocellular carcinoma (HCC), independently of the aetiology of chronic liver disease, and homozygous patients have a worse prognosis [72][73][74][75][76]. The TM6SF2-E167K variant was also associated with NAFLD [53]; it favours progression to NASH and fibrosis by impairing the secretion of very low density lipoproteins in hepatocytes, but protecting from atherosclerosis [59,77].…”

Section: Geneticsmentioning

confidence: 99%

A “systems medicine” approach to the study of non-alcoholic fatty liver disease

Petta

Valenti

Bugianesi

et al. 2016

Digestive and Liver Disease

View full text Add to dashboard Cite

The prevalence of fatty liver (steatosis) in the general population is rapidly increasing worldwide. The progress of knowledge in the physiopathology of fatty liver is based on the systems biology approach to studying the complex interactions among different physiological systems. Similarly, translational and clinical research should address the complex interplay between these systems impacting on fatty liver. The clinical needs drive the applications of systems medicine to re-define clinical phenotypes, assessing the multiple nature of disease susceptibility and progression (e.g. the definition of risk, prognosis, diagnosis criteria, and new endpoints of clinical trials). Based on this premise and in light of recent findings, the complex mechanisms involved in the pathology of fatty liver and their impact on the short- and long-term clinical outcomes of cardiovascular, metabolic liver diseases associated with steatosis are presented in this review using a new "systems medicine" approach. A new data set is proposed for studying the impairments of different physiological systems that have an impact on fatty liver in different subsets of subjects and patients.

show abstract

Section: Geneticsmentioning

confidence: 99%

A “systems medicine” approach to the study of non-alcoholic fatty liver disease

Petta

Valenti

Bugianesi

et al. 2016

Digestive and Liver Disease

View full text Add to dashboard Cite

show abstract

“…NASH may evolve to cirrhosis and hepatocellular carcinoma [9,10]. Although genetic variants influencing lipid droplets remodeling and lipoproteins secretion contribute to NAFLD susceptibility [11], the mechanisms underpinning liver disease progression are not fully understood.…”

Section: Introductionmentioning

confidence: 99%